Home

aboutpic Lon S. Schneider, MD, MS is a professor of psychiatry, neurology, and gerontology at the University of Southern California Keck School of Medicine and Leonard Davis School of Gerontology. He directs the USC State of California Alzheimer’s Disease Research and Clinical Center and the USC National Institute on Aging Alzheimer’s Disease Research Center clinical core. His academic work spans a range of areas in neuropsychopharmacology, cognitive impairment, and Alzheimer’s disease. He holds a master’s degree in biometry and epidemiology and has expertise in clinical trials methods and drug development. He is a co-editor or editorial board member of several publications, including the Cochrane Dementia and Cognitive Improvement Group, Current Alzheimer Research, BMC-Psychiatry, Alzheimer’s & Dementia, The Lancet Neurology, and Clinical Neuropharmacology among others, and has authored numerous papers and book chapters.

The following are links to the USC experts website:
http://www.usc.edu/uscnews/experts/945.html
http://keck.usc.edu/profiles?facid=1022

Linkedin
http://www.linkedin.com/profile/view?id=168265652&trk=hb_tab_pro_top
http://www.linkedin.com/pub/lon-s-schneider/48/427/b58




Some articles and book chapters by Lon S. Schneider

Articles

Schneider LS. A federally funded corporation for the prevention and treatment of cognitive impairment and brain aging. Alzheimer’s & Dementia 2009; 5(2): 172-179.

Schneider LS, Sano M. Current Alzheimer Disease Clinical Trials: Methods and Placebo Outcomes. Alzheimer’s & Dementia 2009; 5(5): 388–397

Schneider LS. The potential and limits for clinical trials for early Alzheimer’s disease and some recommendations Journal of Nutrition, Health & Aging 2010;14(4): 295-298 (Online) DOI 10.1007/s12603-009-0234-3

Schneider LS. Fixing Alzheimer disease trials by improving process and methods. Current Alzheimer Research 2011; 7 (7): 564-565

Schneider LS. Organising the language of Alzheimer’s disease in light of biomarkers. The Lancet Neurology 2010; 9 (11): 1044-1045 Published online October 11, 2010 doi:10.1016/S1474-4422(10)70246-5 1

Golde TE, Schneider LS, Koo EH. Anti-Aβ therapeutics in Alzheimer’s disease: The need for a paradigm shift. Neuron 2011 (27 January); 69 (2): 203-213

Book chapters

Schneider LS. Issues in design and conductance of clinical trials for cognitive-enhancing drugs. In, Animal and Translational Models of Behavioural Disorders, volume 2: Neurological Disorders. Edited by RA McArthur and F Borsini. Elsevier, New York, 2008.

Aisen PS, Cummings J, Schneider LS. Symptomatic and non-amyloid/tau based pharmacologic treatment for Alzheimer disease. In, The Biology of Alzheimer Disease. Edited by Dennis J Selkoe, Eckhard Mandelkow, David M Holtzman. Cold Spring Harbor Laboratory Press, New York 2012; 475-495. Advanced online at http://www.perspectivesinmedicine.org Cold Spring Harb Perspect Med doi: 10.1101 cshperspect.a006395 PMCID: PMC3282492

Schneider LS. Pharmacological treatment of Alzheimer’s disease. In, Alzheimer’s Disease – Modernizing Concept, Biological Diagnosis and Therapy.Adv Biol Psychiatry. Edited by H. Hampel, MC Carrillo: Karger, Basel, 2012; vol 28, pp 122–167 DOI: 10.1159/000335407